Biopharma to Accelerate Alzheimer Trial Completion
Source: Streetwise Reports  (3/25/20)
The upcoming catalysts for Axsome Therapeutics and the effects of COVID-19 on its clinical activities are discussed in an H.C. Wainwright & Co. report. More >

Clinical Catalysts Impending for California-Based Biopharma
Source: Streetwise Reports  (3/18/20)
The firm's three upcoming potential stock movers are reviewed in a ROTH Capital Partners report. More >

iBio Shares Trade Up 40% After Announcing Development of Proprietary COVID-19 Vaccine Candidates
Source: Streetwise Reports  (3/18/20)
iBio Inc. shares traded higher after the company reported that it has filed several provisional patents for its SARS-CoV-2 Virus-Like Particle platform with the U.S. Patent and Trademark Office. More >

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program
Source: Streetwise Reports  (3/17/20)
Shares of Regeneron Pharmaceuticals rose to a new 52-week high price after the company reported it has identified hundreds of virus-neutralizing antibodies and plans to initiate large-scale manufacturing by mid-April of a multi-antibody therapy to treat coronavirus. More >

Predictive Oncology Launches AI Vaccine and Drug Platform & Acquires Technology
Source: Streetwise Reports  (3/12/20)
Shares of Predictive Oncology traded higher after the company reported that it launched a new AI vaccine and drug development platform targeting coronaviruses and acute respiratory syndromes and that it is acquiring Soluble Therapeutics assets including its HSC Technology. More >

AIM ImmunoTech Shares Soar as Japan's NIID Tests Ampligen® as Potential Coronavirus Treatment
Source: Streetwise Reports  (3/9/20)
Shares of AIM ImmunoTech traded more than 150% higher after the company reported that Japan's National Institute of Infectious Diseases will test its Ampligen® drug as a potential treatment for the coronavirus. More >

U.S.-Based Biotech 'Growing into a Giant with AI'
Source: Streetwise Reports  (3/7/20)
How Moderna uses and benefits from digitization and artificial intelligence are described in a ROTH Capital Partners report. More >

Avivagen to Be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD on March 6
Source: Streetwise Reports  (3/5/20)
Webcast will be at 12 noon ET on Friday, March 6. More >

Antibody Developer Taken Out by Gilead at 'Hefty Premium'
Source: Streetwise Reports  (3/4/20)
The reasons Forty Seven attracted a buyer and its near-term catalysts are provided in a BTIG report. More >

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data
Source: Streetwise Reports  (3/4/20)
Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. More >

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results
Source: Streetwise Reports  (3/2/20)
Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. More >

Sangamo Shares Trade 30% Higher on Q4 Earnings and Biogen Collaboration
Source: Streetwise Reports  (2/28/20)
Sangamo Therapeutics shares traded higher after the company reported Q4/19 and FY/19 earnings and advised that it signed a global collaboration agreement with Biogen to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular and neurological diseases. More >

Moderna Shares Climb on Development of mRNA Vaccine for Phase 1 Coronavirus Study
Source: Streetwise Reports  (2/25/20)
Shares of Moderna traded 23% higher after the company reported that it has developed and shipped an mRNA vaccine against novel coronavirus for use in a Phase 1 testing study in the U.S. More >

Two Stock-Moving Catalysts Expected in March for Biopharma
Source: Streetwise Reports  (2/25/20)
These events for Axsome Therapeutics are described in an H.C. Wainwright & Co. report. More >

NGM Biopharma Shares Rise on Positive Topline Data from Phase 2 NASH Trial
Source: Streetwise Reports  (2/24/20)
Shares of NGM Biopharmaceuticals reached a new 52-week intraday high price after the company posted positive topline data from Cohort 4 of its Phase 2 study of aldafermin in NASH Patients. More >

Antibiotic-Free Feed Additive Shows Benefit in Cow Mastitis Trial
Source: Streetwise Reports  (2/24/20)
Avivagen's proprietary product yielded statistically significant results. More >

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication
Source: Streetwise Reports  (2/21/20)
Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESOâ„¢ drug for management of moderate to severe pain. More >

FDA Approval of Biopharma's Pain Drug Expected This Year
Source: Streetwise Reports  (2/19/20)
The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. More >

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation
Source: Streetwise Reports  (2/18/20)
Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. More >

Life Sciences Firm Contracts with Philippines Distributor
Source: Streetwise Reports  (2/18/20)
This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product. More >

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates
Source: Streetwise Reports  (2/14/20)
Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. More >

vTv Therapeutics' Shares Open 80% Higher on Phase 2 Type 1 Diabetes Trial Data
Source: Streetwise Reports  (2/10/20)
Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. More >

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases
Source: Streetwise Reports  (2/8/20)
The events in that trio are presented in a ROTH Capital Partners report. More >

Cortexyme Secures $125M Private Placement Capital to Advance Clinical Development
Source: Streetwise Reports  (2/6/20)
Shares of Cortexyme Inc. traded 20% higher after the company reported that it secured an additional $125M in capital from a private placement. The firm intends to use the proceeds to fund current Alzheimer's clinical trials and ongoing operations. More >

Vivus Shares Climb 50% Higher on sNDA Approval for Exocrine Pancreatic Insufficiency Drug
Source: Streetwise Reports  (2/5/20)
Shares of Vivus traded higher after the FDA approved the company's supplemental New Drug Application for an improved formulation of PANCREAZE® (pancrelipase) for use in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. More >